Form 4: HCA Healthcare CEO Hazen Reports Stock Transactions

HCA Healthcare CEO Samuel N. Hazen reported the exercise of stock appreciation rights, acquisition of common stock, and subsequent sale for tax obligations, alongside a new grant of stock appreciation rights.

Summary

• CEO Samuel N. Hazen exercised 84,360 stock appreciation rights (SARs) at an exercise price of $81.96 on January 30, 2026.
• This exercise resulted in the acquisition of 84,360 shares of HCA Healthcare common stock.
• Concurrently, 41,483 shares of common stock were disposed of at a price of $488.27 to cover tax liabilities related to the SARs exercise.
• Following these transactions, Hazen directly holds 75,153 shares of common stock.
• Hazen also received a new grant of 55,846 stock appreciation rights on January 29, 2026, with an exercise price of $482.53.
• These new SARs will vest in four equal annual installments starting January 29, 2027, and expire on January 29, 2036.
• Hazen's indirect beneficial ownership includes shares held by various trusts and an LP, totaling 1,316,407 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a routine insider transaction that includes both the realization of past equity gains and the establishment of new long-term incentives for the CEO, indicating continued commitment.

Positives

• CEO Hazen received a new grant of 55,846 Stock Appreciation Rights, indicating continued incentive alignment with company performance.
• The exercise of SARs at $81.96 and subsequent disposition of shares at $488.27 demonstrates a significant in-the-money value for the exercised derivatives, reflecting past stock price appreciation.

Negatives

• A substantial number of shares (41,483) were disposed of to cover tax liabilities, which is a common practice but reduces direct ownership.

Risks

• NA

Future Outlook

The grant of new Stock Appreciation Rights with a vesting schedule extending to 2027 and an expiration date in 2036 indicates a long-term incentive structure for the CEO, aligning his interests with future company performance.

Management Comments

• NA

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity-based incentives like Stock Appreciation Rights, is a common practice in the healthcare industry to align management's interests with shareholder value. The significant value realized from the exercised SARs suggests HCA Healthcare's stock has performed well over the vesting period, potentially outperforming some peers in the hospital and healthcare services sector.

Comparison to Industry Standards

• NA (This Form 4 filing details insider transactions and does not provide performance metrics for comparison to industry standards or specific competitors.)

Related Party Transactions

• Indirect beneficial ownership through HD Trust, 2023 GST Trust, 2023 Trust, 2024 GRAT, 2025 GRAT, and LP, which are likely related entities to the reporting person.

Stakeholder Impact

• Shareholders: The CEO's continued equity ownership and new SAR grant align his interests with shareholder value creation. The disposition of shares for tax purposes is a routine event and does not indicate a lack of confidence.
• Employees: No direct impact on employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• The newly granted Stock Appreciation Rights will begin vesting in four equal annual installments starting January 29, 2027.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions, including the exercise of stock appreciation rights, a tax-related disposition of shares, and a new grant of equity incentives. These actions are typical for executive compensation and do not signal a material change in the company's fundamentals or the CEO's long-term commitment. While the tax-related sale reduces direct ownership, the new SAR grant reinforces alignment with future shareholder value. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment stance.

Keywords

HCA Healthcare, HCA, Samuel N Hazen, CEO, Stock Appreciation Rights, SARs, Insider Trading, Form 4, Stock Transactions, Equity Compensation